Literature DB >> 24971706

Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores.

Omodele Ashiru1, Jonathon D Howe2, Terry D Butters3.   

Abstract

Nitazoxanide (NTZ) inhibits influenza, Japanese encephalitis, hepatitis B and hepatitis C virus replication but effects on the replication of other members of the Flaviviridae family has yet to be defined. The pestivirus bovine viral diarrhoea virus (BVDV) is a surrogate model for HCV infection and NTZ induced PKR and eIF2α phosphorylation in both uninfected and BVDV-infected cells. This led to the observation that NTZ depletes ATP-sensitive intracellular Ca(2+) stores. In addition to PKR and eIF2α phosphorylation, consequences of NTZ-mediated Ca(2+) mobilisation included induction of chronic sub-lethal ER stress as well as perturbation of viral protein N-linked glycosylation and trafficking. To adapt to NTZ-mediated ER stress, NTZ treated cells upregulated translation of Ca(2+)-binding proteins, including the ER chaperone Bip and the cytosolic pro-survival and anti-viral protein TCTP. Depletion of intracellular Ca(2+) stores is the primary consequence of NTZ treatment and is likely to underpin all antiviral mechanisms attributed to the thiazolide.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ER stress; Flaviviridae; Intracellular Ca(2+); N-linked glycans; PKR; TCTP

Mesh:

Substances:

Year:  2014        PMID: 24971706     DOI: 10.1016/j.virol.2014.05.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Authors:  Yi Qu; Jan Roger Olsen; Xing Yuan; Phil F Cheng; Mitchell P Levesque; Karl A Brokstad; Paul S Hoffman; Anne Margrete Oyan; Weidong Zhang; Karl-Henning Kalland; Xisong Ke
Journal:  Nat Chem Biol       Date:  2017-10-30       Impact factor: 15.040

Review 2.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

3.  Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika.

Authors:  Rui-Yuan Cao; Yong-Fen Xu; Tian-Hong Zhang; Jing-Jing Yang; Ye Yuan; Pei Hao; Yi Shi; Jin Zhong; Wu Zhong
Journal:  Open Forum Infect Dis       Date:  2017-02-03       Impact factor: 3.835

4.  Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells.

Authors:  Hongzhuan Zhou; Xia Su; Lulu Lin; Jin Zhang; Qi Qi; Fangfang Guo; Fuzhou Xu; Bing Yang
Journal:  Viruses       Date:  2019-08-13       Impact factor: 5.048

5.  Therapeutic potential of Nitazoxanide against Newcastle disease virus: A possible modulation of host cytokines.

Authors:  Ferrin Antony; Yoya Vashi; Sudhir Morla; Hari Mohan; Sachin Kumar
Journal:  Cytokine       Date:  2020-05-03       Impact factor: 3.861

6.  The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus.

Authors:  Luke D Jasenosky; Cristhian Cadena; Chad E Mire; Viktoriya Borisevich; Viraga Haridas; Shahin Ranjbar; Aya Nambu; Sina Bavari; Veronica Soloveva; Supriya Sadukhan; Gail H Cassell; Thomas W Geisbert; Sun Hur; Anne E Goldfeld
Journal:  iScience       Date:  2019-08-08

Review 7.  Broad-spectrum antiviral agents.

Authors:  Jun-Da Zhu; Wen Meng; Xiao-Jia Wang; Hwa-Chain R Wang
Journal:  Front Microbiol       Date:  2015-05-22       Impact factor: 5.640

8.  Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency.

Authors:  Ludmila Perelygina; Timo Hautala; Mikko Seppänen; Adebola Adebayo; Kathleen E Sullivan; Joseph Icenogle
Journal:  Antiviral Res       Date:  2017-09-30       Impact factor: 5.970

Review 9.  Nitazoxanide: a first-in-class broad-spectrum antiviral agent.

Authors:  Jean-François Rossignol
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

10.  Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenza virus therapies.

Authors:  Jiayu Liao; George Way; Vipul Madahar
Journal:  Med Drug Discov       Date:  2020-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.